17 December 2013 - Novartis Pharmaceuticals Canada Inc. announced today that Health Canada has approved the use of Ilaris (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years and older. SJIA is a rare and disabling form of childhood arthritis with limited treatment options. The condition is characterized by spiking fever, rash and arthritis that can affect children as young as two years old and can continue into adulthood.

For more details, go to: http://www.novartis.ca/downloads/en/News/PR-ILARIS-121713-EN.pdf